Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 4334
Journal of Alzheimers Disease & Parkinsonism received 4334 citations as per Google Scholar report
Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Novel therapeutic strategies for alzheimer′s disease: Neurotrophy and neurorestoration
10th World Congress on Alzheimer's Disease & Dementia
Jun Liu
Sun Yat-sen University, China
ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism
Abstract
Alzheimerâ??s Disease (AD) is a neurodegenerative disorder mainly characterized by ?²-amyloid deposit, Ï?-hyperphosphorylation and neuron loss with no curative treatments. In recent years, the main efforts of multinational pharmaceutical companies have been focused on reducing the aggregation of A?² and Ï?-proteins but with repeated defeats. According to statistics of Adis R&D, between 1998 and 2014, major pharmaceutical companies launched a total of 123 drugs for AD but only three drugs and one combination therapy program have been approved by the FDA. However, without exception, none of these 123 drugs can cure AD and even delay the progression of the disease. So we should shift our focus from alleviating the AD-like pathologies to neuroprotection, which means the preservation of neuronal structure and/or function. As far as we know, there are some therapeutic strategies of neuroprotection for AD, such as the application of NMDA receptor antagonists, Acetylcholinesterase Inhibitors (ACEIs), anti-inflammatory agents, antioxidants, neurotrophins and Chinese medicine and so on. Our research group has found that neurotropin (a non-protein bioactive agent extracted from rabbit inflamed skins inoculated with Vaccinia virus vaccine), GQDG (Graphene Quantum Dot Conjugated with neuroprotective peptide-glycine-proline-glutamate), edaravone, EGb761 (Ginkgo Biloba extract) and ?²-sitosterol exerted potent neuroprotective effects in AD. In conclusion, a single cure for AD is unlikely to be found and multi-target therapies should be addressed.Biography
Jun Liu has completed his PhD from Sun Yat-sen University and Postdoctoral studies from University of Kansas Medical School. He is currently the Vice Director of Neurology Department of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. He has been investigating the pathologies and therapeutics of Alzheimer’s disease and published more than 22 SCI papers as the corresponding author.
Email:docliujun@hotmail.com
